natgillin/translations-raw huggingface dataset:
After administration of a single dose of 50 mg Teysuno (expressed as tegafur content) in man (approximately 30 mg/m2 based on body surface area of 1.56 to 2.10 m2 for a typical patient; N=14), the median Tmax for Teysuno components tegafur, gimeracil, and oteracil was 0.5, 1.0, and 2.0 hours, respectively, and the mean ± standard deviation (SD) AUC0-inf and Cmax was 14595 ± 4340 ng.hr/ml and 1762 ± 279 ng/ml for tegafur, 1884 ± 640 ng.hr/ml and 452 ± 102 ng/ml for gimeracil,
Po uporabi enkratnega odmerka 50 mg zdravila Teysuno (izraženo z vsebnostjo tegafurja) pri moških (približno 30 mg/m2 na osnovi telesne površine od 1,56 do 2,10 m2 za tipičnega bolnika; N = 14) je mediana Tmax za sestavine zdravila Teysuno tegafur, gimeracil in oteracil znašala 0,5, 1,0 in 2,0 ure, in sicer v tem zaporedju, povprečje ± standardni odklon (SD) AUC0-inf in Cmax pa 14595 ± 4340 ng.hr/ml in 1762 ± 279 ng/ml za tegafur, 1884 ± 640 ng.hr/ml in 452 ± 102 ng/ml za gimeracil ter
After administration of a two-fold overdose a rectal temperature increase of up 2.1ºC may occur 1 day after the injection and then rectal temperatures return to normal values.
Po dajanju dvojnega odmerka se lahko 1 dan po injiciranju pojavi povišenje rektalne temperature, ki ne presega 2,1 °C. Nato se rektalna temperatura vrne na normalno vrednost.
After administration of a two-fold overdose, a rectal temperature increase of up 2.1 ºC may occur 1 day after the injection and then rectal temperatures return to normal values.
Po dajanju dvojnega odmerka se lahko 1 dan po injiciranju pojavi povišanje rektalne temperature, ki ne presega 2,1°C. Nato se rektalna temperatura vrne na normalno vrednost.
After administration of Amyvid, you should:
Po prejemu zdravila Amyvid se morate:
After administration of any asparaginase preparation, close monitoring of bilirubin, hepatic transaminases, blood/urinary glucose, coagulation parameters (e.g.
Po dajanju katerega koli zdravila z asparaginazo je priporočljivo skrbno spremljanje bilirubina, jetrnih transaminaz, glukoze v krvi/urinu, koagulacijskih parametrov (npr.
After administration of asparaginase, close monitoring of bilirubin, hepatic transaminases, of blood/urinary glucose, coagulation parameters (PTT, PT, antithrombin III, fibrinogen, and D-dimer), amylase, lipase, triglycerides, and cholesterol is recommended.
Po uporabi asparaginaze je priporočljivo skrbno spremljanje bilirubina, jetrnih transaminaz, glukoze v krvi in urinu, koagulacijskih parametrov (PTČ, PČ, antitrombin III, fibrinogen in D-dimer), amilaze, lipaze, trigliceridov in holesterola.
After administration of enoxaparin sodium, the injection site should not be rubbed.
Mesta injiciranja po aplikaciji natrijevega enoksaparinata ne masirajte.
After administration of epoetin delta, the number of erythrocytes, the Hb values and reticulocyte counts increase as well as the 59Fe- incorporation rate.
Po uporabi epoetina delta se zvečajo število eritrocitov, koncentracija hemoglobina, število retikulocitov in hitrost vgradnje 59Fe.
After administration of erythropoietin, the number of erythrocytes, the Hb values and reticulocyte counts increase as well as the 59Fe-incorporation rate.
Po injiciranju eritropoetina se dvigne tako število eritrocitov, vrednosti Hb in število retikulocitov, kot tudi hitrost vgrajevanja 59Fe.
After administration of multiple dose of 400 mg or 300 mg of Abilify Maintena, the mean aripiprazole terminal elimination half-life is respectively 46.5 and 29.9 days presumably due to absorption rate- limited kinetics.
Po večkratnem odmerjanju zdravila Abilify Maintena 400 mg ali 300 mg je srednji razpolovni čas izločanja aripiprazola približno 46,5 dneva in 29,9 dneva, domnevno zaradi kinetike, omejene s hitrostjo absorpcije.
After administration of NUEDEXTA 23 mg/9 mg to 14 extensive metabolizers, the elimination half- life of dextromethorphan was 18.8 hours and the elimination half-life of quinidine was 9.6 hours.
Po dajanju zdravila NUEDEXTA 23 mg/9 mg 14 osebam z obsežno presnovo je bil razpolovni čas izločanja dekstrometorfana 18,8 ure, razpolovni čas izločanja kinidina pa je bil 9,6 ure.
After administration of pantoprazole to patients with liver impairment (Child-Pugh classes A, B and C) the half-life values increased to between 3 and 7 h and the AUC values increased by a factor of 3-6, whereas the Cmax only increased slightly by a factor of 1.3 compared with healthy subjects.
Pri uporabi pantoprazola pri bolnikih z okvaro jeter (razredi A, B in C po Child-Pugh-u) se, v primerjavi z zdravimi osebami, razpolovni čas podaljša na 3 do 7 ur, vrednosti AUC zvišajo za 3- do 6- krat, vrednost Cmax pa se komaj opazno zviša, in sicer za faktor 1,3.
After administration of Praxbind, other antithrombotic therapy (e.g. low-molecular weight heparin) can be started at any time, if the patient is clinically stable and adequate haemostasis has been achieved.
Po dajanju zdravila Praxbind lahko drugo antitrombotično terapijo (npr. nizkomolekularni heparin) uvedemo kadarkoli, če je bolnik klinično stabilen in je bila dosežena ustrezna hemostaza.
After administration of Scintimun
Po dajanju zdravila Scintimun
After administration of sugammadex at reappearance of T2 following a rocuronium induced blockade, the median time to recovery of the T4/T1 ratio to 0.9 in adults (18-64 years) was 2.2 minutes, in elderly adults (65-74 years) it was 2.6 minutes and in very elderly adults (75 years or more) it was
Po dajanju sugamadeksa pri ponovnem pojavu T2 po blokadi živčnomišičnega prenosa z rokuronijem znaša mediana vrednost časa do povrnitve razmerja T4/T1 na 0,9 pri odraslih (starih od 18 do 64 let) 2,2 minuti, pri starostnikih (starih od 65 do 74 let) 2,6 minut in pri zelo starih bolnikih (starih 75 let ali več) 3,6 minut.
After administration of the combination product, protein binding remains essentially the same as that after administration of the individual components; dextromethorphan is approximately 60-70% protein bound, and quinidine is approximately 80-89% protein bound.
Po dajanju kombiniranega zdravila ostaja vezava na beljakovine v osnovi enaka kot po dajanju posameznih sestavin; na beljakovine se veže približno 60–70 % dekstrometorfana in 80–89 % kinidina.
After administration of the efavirenz-food mixture, an additional small amount (approximately 2 teaspoons) of food must be added to the empty mixing container, stirred to disperse any remaining residue of the medicinal product, and administered to the patient.
Po zaužitju mešanice hrane in zdravila efavirenz je treba dati v prazno posodo, v kateri ste pripravljali mešanico, še manjšo količino hrane (približno 2 čajni žlički) ter pomešati, da se zajame še morebitne ostanke zdravila na posodi, ter dati bolniku, naj hrano zaužije.
After administration of the recommended dose lung concentrations of 0.060–0.066 µg/ml were found at 2 and 12 hours post-treatment.
Dve uri in 12 ur po dajanju priporočenega odmerka so ugotovili v pljučih koncentracije 0,060 - 0,066 µg/ml.
After administration of the recommended dose lung concentrations of 0.060–0.066 µg/ml were found at 2 and 12 hours post-treatment.
Po dajanju priporočenega odmerka je bila v pljučih izmerjena koncentracija 0.060-0.066 µg/ml 2 uri in 12 ur po dajanju.
After administration of the required volume from the 5 ml syringe with the dissolved suspension of raltegravir, the remaining suspended medicine cannot be re-used and should be discarded (see section 6.6).
Po dajanju potrebnega volumna pripravljene suspenzije raltegravirja s pomočjo 5-ml brizge za peroralno dajanje se preostale suspenzije ne sme ponovno uporabiti in jo je treba zavreči (glejte poglavje 6.6).
After administration of the veterinary medicinal product close the bottle tightly with the cap, wash the measuring syringe with water and let it dry.
Po uporabi zdravila za uporabo v veterinarski medicini stekleničko dobro zaprite z zaporko, splaknite merilno brizgo z vodo in jo pustite, da se posuši.
After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.
Po dajanju zdravila za uporabo v veterinarski medicini plastenko zaprite z zaporko in merilno brizgo pomijte s toplo vodo in posušite
After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.
Po dajanju zdravila za uporabo v veterinarski medicini vsebnik ponovno zaprite s pokrovčkom in merilno brizgo pomijte s toplo vodo in posušite
After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.
Po dajanju zdravila, vsebnik ponovno zaprite pokrovčkom, merilno brizgo operite s toplo vodo in pustite, da se posuši.
After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.
Po dajanju zdravila, vsebnik ponovno zaprite s pokrovčkomin merilno brizgo pomijte s toplo vodo in posušite
After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.
Po dajanju zdravila, vsebnik ponovno zaprite s pokrovčkomin merilno brizgo pomijte s toplo vodo in posušite.
After administration of this medicinal product, an interval of at least 3 months should elapse before vaccination with live attenuated virus vaccines.
Po dajanju tega zdravila morajo pred cepljenjem z živimi atenuiranimi virusnimi cepivi preteči vsaj 3 meseci.
After administration of this medicinal product, an interval of at least 3 months should elapse before vaccination with live attenuated virus vaccines.
Po uporabi tega zdravila morajo preteči vsaj trije meseci pred cepljenjem s cepivom, ki vsebuje živ, oslabljen virus.
After administration of up to 10 times the recommended dose (2.5 mg/kg bw benazepril hydrochloride, 20 mg/kg bw spironolactone) to healthy dogs, dose dependant adverse effects were noted (see section 4.6).
Po dajanju do 10 krat večjega odmerka od priporočenega (20 mg/kg t.m. spironolaktona, 2,5 mg/kg t.m. benazeprilijevega hidroklorida) zdravemu psu, so bili opaženi od odmerka odvisni neželeni učinki (glej poglavje 4.6).
After administration of up to 10 times the recommended dose (2.5 mg/kg bw benazepril hydrochloride, 20 mg/kg spironolactone) to healthy dogs, dose dependent adverse effects were noted, see section "Adverse reactions".
Po dajanju do 10 krat večjega odmerka od priporočenega (20 mg/kg t.m. spironolaktona, 2,5 mg/kg t.m. benazepril hidroklorida) zdravemu psu, so bili opaženi od odmerka odvisni neželeni učinki (glej poglavje ''Neželeni učinki'').
After administration of up to 10 times the recommended dose (20 mg/kg) to healthy dogs, dose- dependent adverse effects were noted (see section "Adverse Reactions").
Po dajanju preko 10-kratnega priporočenega odmerka (20 mg/kg) zdravemu psu, so opazili neželene učinke odvisne od odmerka, (glej poglavje "Neželeni učinki")..
After administration of up to 10 times the recommended dose (20 mg/kg) to healthy dogs, dose- dependent adverse effects were noted (see section 4.6).
Po administraciji preko 10-kratnega priporočenega odmerka (20 mg/kg) zdravemu psu, so opazili neželene učinke odvisne od odmerka (glej poglavje 4.6).
After administration of up to 5-fold of the recommended dose for 6 months, no adverse reactions were observed other than those mentioned in section "Adverse reactions".
Po dajanju do 5-kratnega priporočenega odmerka 6 mesecev niso opazili nobenih neželenih učinkov, razen tistih, omenjenih v poglavju 4.6 "Neželeni učinki".
After administration of up to 5-fold of the recommended dose for 6 months, no adverse reactions were observed other than those mentioned in section 4.6.
Po dajanju do 5-kratnega priporočenega odmerka 6 mesecev niso opazili nobenih neželenih učinkov, razen tistih, omenjenih v poglavju 4.6.
After administration of VIZAMYL
Po odmerjanju zdravila VIZAMYL
After administration of Xofigo
Po uporabi zdravila Xofigo
After administration, ceftiofur is quickly metabolised to desfuroylceftiofur, the principal active metabolite.
Po dajanju se ceftiofur hitro metabolizira v desfurojilceftiofur, glavni aktivni metabolit.
After administration, change gloves prior to applying occlusive dressings to injected lesions.
Po injiciranju zdravila zamenjajte rokavice, preden namestite okluzivni povoj na spremembe, v katere ste injicirali.
After administration, fluoxetine readily appeared in plasma with mean Tmax values ranging from 1.25 to 1.75 hours on day 1 and from 2.5 to 2.75 hours on day 21.
Po zaužitju se je fluoksetin hitro pokazal v plazmi, pri čemer so povprečne vrednosti Tmax 1. dan segale od 1,25 do 1,75 ur in 21. dan od 2,5 do 2,75 ur.
After administration, occasionally sneezing, coughing, mild and transient discharge from the eyes or nose, may occur.
Občasno se po dajanju lahko pojavi kihanje, kašelj, blag in prehoden izcedek iz oči ali nosu.
After administration: Throw away any remaining solution as it should not be used beyond 20 minutes.
Po dajanju: Preostanek raztopine je treba zavreči, saj se ga po 20 minutah ne sme več uporabiti.
After adminstration of Lymphoseek, you should?
Po prejemu zdravila Lymphoseek:
After an acute coronary syndrome patients on treatment with Xarelto and ASA or Xarelto and ASA plus clopidogrel/ticlopidine should only receive concomitant treatment with NSAIDs if the benefit outweighs the bleeding risk.
Po akutnem koronarnem sindromu naj bolniki, ki se zdravijo z zdravilom Xarelto in acetilsalicilno kislino ali zdravilom Xarelto in acetilsalicilno kislino in klopidogrelom/tiklopidinom, sočasno prejemajo NSAID samo, če koristi pretehtajo možna tveganja za krvavitve.
After an average of 36 months of treatment, the mean annualised rate of change in eGFRCKD-EPI was -0.81 mL/min/1.73 m2 (95% CI: -2.00, 0.37).
Po povprečno 36 mesecih zdravljenja je bila srednja letna stopnja spremembe eGFRCKD-EPI –0,81 ml/min/1,73 m2 (95-% CI: –2,00, 0,37).
After an increase in dose, an additional test will be done after 2 weeks.
Po zvišanju odmerka bo po 2 tednih opravljena še ena dodatna preiskava.
After an initial increase in visual acuity (following monthly dosing), on average, patients’ visual acuity declined with quarterly dosing, returning to baseline at Month 12 and this effect was maintained in most ranibizumab-treated patients (82%) at Month 24.
V povprečju se je ostrina vida pri bolnikih ob enkrat mesečnem odmerjanju zdravila Lucentis sprva izboljšala, kasneje ob odmerjanju enkrat na tri mesece poslabšala in se po 12 mesecih vrnila na izhodiščno raven; ta učinek je 24 mesecev po začetku študije ostal ohranjen pri večini bolnikov, ki so prejemali ranibizumab (pri 82 %).
after an operation or long periods of bed rest due to illness
po operaciji ali po daljšem okrevanju v postelji zaradi bolezni,
After an oral dose of metformin, tmax is reached in 2.5 h.
Po peroralnem odmerku metformina je tmax dosežen v 2,5 urah.
After an oral dose of metformin, tmax is reached in 2.5 h.
Po peroralnem odmerku metformina je vrednost tmax dosežena v 2,5 ure.
After an oral dose of metformin, tmax is reached in 2.5 h.
Po peroralni uporabi metformina je tmax dosežen v 2,5 ure.
After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%.
Po peroralnem odmerjanju je bil neabsorbirani delež v blatu 20–30 %.
After an oral glucose load, this DPP4 inhibition resulted in a 2- to 3-fold increase in circulating levels of active incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness, which resulted in higher insulin and C-peptide concentrations.
Po peroralni obremenitvi z glukozo je to zavrtje DPP-4 povzročilo 2- do 3-kraten porast koncentracije aktivnih inkretinskih hormonov v obtoku vključno z glukagonu podobnim peptidom-1 (GLP-1) in od glukoze odvisnim insulinotropnim polipeptidom (GIP), zmanjšalo je koncentracijo glukagona in povečalo od glukoze odvisno odzivnost celic beta, zaradi česar sta se povečali koncentracija insulina in C-peptida.
After an oral glucose load, this DPP4 inhibition resulted in a 2-to 3-fold increase in circulating levels of active incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness, which resulted in higher insulin and C-peptide concentrations.
Po peroralni obremenitvi z glukozo je to zavrtje DPP4 povzročilo 2- do 3-kratno povečanje koncentracije aktivnih inkretinskih hormonov v obtoku (vključno z glukagonu podobnim peptidom-1 (GLP-1) in od glukoze odvisnim insulinotropnim polipeptidom (GIP)), zmanjšalo koncentracijo glukagona in povečalo od glukoze odvisno odzivnost celic beta, zaradi česar sta se povečali koncentracija insulina in C-peptida.
After an oral glucose load, this produced in a 2- to 3-fold increase in circulating levels glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), decreased glucagon concentrations, and increased beta-cell responsiveness, resulting in higher insulin and C-peptide concentrations.
Po peroralni obremenitvi z glukozo je to povzročilo 2- do 3-kratno zvišanje koncentracije glukagonu podobnega peptida-1 (GLP-1 - glucagon-like peptide-1) in od glukoze odvisnega insulinotropnega polipeptida (GIP - glucose-dependent insulinotropic polypeptide) v obtoku, znižalo je koncentracijo glukagona in povečalo odzivnost celic beta, zaradi česar sta se zvišali koncentracija insulina in peptida.
After any dose or schedule adjustment the haemoglobin should be monitored every one or two weeks.
Po vsaki prilagoditvi odmerka ali odmerne sheme je treba koncentracijo hemoglobina spremljati na en do dva tedna.
After application, the active substance of Ameluz becomes a photoactive substance which accumulates in affected cells.
Po nanosu se zdravilna učinkovina zdravila Ameluz spremeni v fotoaktivno snov, ki se kopiči v prizadetih celicah.
After applying NexoBrid
Po nanosu zdravila NexoBrid
after around 12 and 24 weeks (end of maintenance phase), and thereafter when clinically indicated.
po približno 12 in 24 tednih (na koncu vzdrževalne faze) ter pozneje, ko je to klinično indicirano.
after around 3 weeks,
po približno 3 tednih,
after around 6 weeks (end of acute phase),
po približno 6 tednih (na koncu akutne faze),
After assessment of the symptoms, the dose of Invega can be adjusted to between 3 and 12 mg once a day in adults with schizophrenia and to between 6 and
Odmerek zdravila Invega se lahko pri odraslih bolnikih s shizofrenijo prilagodi glede na simptome v razponu od 3 do 12 mg enkrat dnevno, pri bolnikih s shizoafektivno motnjo pa od 6 do 12 mg enkrat dnevno.
After at least one week, the dose is increased to 1.2 mg.
Po najmanj enem tednu se odmerek poveča na 1,2 mg.
After at least one week, the dose should be increased to 1.2 mg.
Po vsaj enem tednu je treba odmerek povečati na 1,2 mg.
After baseline and placebo adjustment, the maximum mean QTcF change was 3.2 ms (1-sided 95% Upper CI: 5.6 ms) for the 500/200 mg dose and 8.3 ms (1-sided 95% Upper CI: 10.8 ms) for the supra-therapeutic 750/200 mg dose.
Po prilagoditvi izhodiščnega stanja in placeba je bila največja srednja sprememba QTcF 3,2 milisekunde (enosmerni 95-odstotni zgornji IZ: 5,6 milisekunde) pri odmerkih po 500/200 mg in 8,3 milisekunde (enosmerni 95-odstotni zgornji IZ: 10,8 milisekunde) pri supraterapevtskih odmerkih po 750/200 mg.
After being given its actions last for 12 weeks against fleas and 8 to 12 weeks against ticks.
Po uporabi zdravilo proti bolham deluje 12 tednov, proti klopom pa od 8 do 12 tednov.
After being given its actions last for 12 weeks against fleas and ticks.
Po nanosu zdravilo proti bolham in klopom deluje 12 tednov.
After being given, its actions last for 5 weeks against fleas and one month against ticks.
Po uporabi zdravilo proti bolham deluje 5 tednov, proti klopom pa en mesec.
After being given, its actions last for 5 weeks against fleas and one month against ticks.
Zdravilo po prejemu učinkuje 5 tednov proti bolham in en mesec proti klopom.
After being properly trained and with the agreement of their doctor, patients may inject themselves.
Potem ko so bolniki ustrezno usposobljeni in s privolitvijo njihovega zdravnika, si lahko zdravilo injicirajo sami.
After being trained by the doctor or specialized nurse, you can inject Strensiq yourself at home.
Zdravilo Strensiq si lahko injicirate sami doma, ko vas bo zdravnik ali specializirana medicinska sestra poučil, kako se to dela.
After cap is removed, if a tamper evident snap collar is present and is loose, remove before using product.
Če je varnostni obroček po odstranitvi zaporke prisoten in ohlapen, ga pred uporabo zdravila odstranite.
After cap is removed, if tamper evident snap collar is loose, remove before using the product.
Če je varnostni obroček po odstranitvi zaporke ohlapen, ga pred uporabo zdravila odstranite.
After cap is removed, if the tamper evident snap collar is loose, remove before using the medicinal product.
Če je varnostni obroček po odstranitvi zaporke ohlapen, ga je treba pred uporabo zdravila odstraniti.
After cap is removed, if the tamper evident snap collar is loose, remove before using the product.
Če je varnostni obroček ohlapen po odstranitvi zaporke, ga odstranite pred uporabo zdravila.
After cartridge insertion
Po vstavitvi vložka
After chemotherapy, one 80 mg capsule
Po kemoterapiji je treba
After chickenpox, the varicella-zoster virus stays in the body, in the nervous system, in a ‘dormant’ (inactive) state.
Po noricah ostane virus varicella-zoster v telesu v živčnem sistemu v „speči“ (neaktivni) obliki.
After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mm Hg).
Po kroničnem odmerjanju 80 mg trikrat na dan pri bolnikih s pljučno arterijsko hipertenzijo so opažali manjše učinke na znižanje krvnega tlaka (znižanje sistoličnega in diastoličnega tlaka za 2 mmHg).
After chronic dosing of 80 mg three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mm Hg and 9.1 mm Hg respectively.
Po kroničnem odmerjanju 80 mg trikrat na dan pri bolnikih s sistemsko hipertenzijo je bila povprečna sprememba sistoličnega krvnega tlaka v primerjavi z izhodiščem znižanje za 9,4 mmHg, diastoličnega pa znižanje za 9,1 mmHg.
After chronic oral dosing of 80 mg three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mm Hg respectively.
Po kroničnem peroralnem odmerjanju 80 mg trikrat na dan pri bolnikih s sistemsko hipertenzijo je bila povprečna sprememba sistoličnega krvnega tlaka v primerjavi z izhodiščem znižanje za 9,4 mmHg, diastoličnega pa znižanje za 9,1 mmHg.
After cleaning
Po čiščenju
After cleaning do not touch the top of the vial.
Očiščenega vrha viale se ne dotikajte.
After clinical reassessment dose may be adjusted within the range 150 mg to 300 mg every 2 weeks or 300 to 405 mg every 4 weeks. (Table 1)
Po ponovni klinični oceni lahko prilagodimo odmerek v razponu 150 mg do 300 mg vsake 2 tedna ali 300 do 405 mg vsake 4 tedne. (Tabela 1)
After co- administration of spironolactone (2 mg/kg bw) and benazepril hydrochloride (0.25 mg/kg bw) the terminal plasma half-lives (t½) were 7 hours and 6 hours for canrenone and 7-α-thiomethyl- spironolactone respectively.
Po hkratnem dajanju benazeprilijevega hidroklorida (0.25 mg/kg t.m.) in spironolaktona (2 mg/kg t.m.) je bil terminalni razpolovni plazemski čas (t½) 7 ur in 6 ur za kanrenon in 7-α-tiometil-spironolakton.
After co-administration of spironolactone (2 mg/kg bw) and benazepril hydrochloride (0.25 mg/kg bw) the terminal plasma half-life of benazeprilat (t½) was 18 hours.
Po hkratnem dajanju benazeprilijevega hidroklorida (0.25 mg/kg t.m.) in spironolaktona (2 mg/ kg t.m.) je terminalni razpolovni plazemski čas benazeprila (t½) 18 ur.